Keros Group

Keros Group company information, Employees & Contact Information

Explore related pages

Related company profiles:

Cabinet de recrutement en chasse de têtes et freelancing, Keros est composée de plusieurs entités répondant chacune à nos différentes expertises : - Keros IT : recrutement par approche directe de cadres dans le domaine de l'informatique et du digital - Keros Executive : recrutement par approche directe de cadres dirigeants (COMEX/CODIR & N-1) et managers de transitions - Keros Sales & Marketing: recrutement par approche directe de cadres dans le domaine du marketing et de la vente Nous sommes le fruit de la rencontre de nos deux fondateurs, Richard et Adrien, dont le chemin s’est croisé lors d’une expérience au sein d’un cabinet de recrutement international. Nourris par la même passion du recrutement et des innovations technologiques, nos fondateurs ont eu pour vocation de créer un cabinet de recrutement moderne, agile, remettant au centre nos clients et nos candidats. Nous proposons les services suivants : - Recrutement en CDI par approche directe - Freelancing et prestations intellectuelle - RPO - Conseil RH

Company Details

Employees
12
Address
60, Rue François 1er, Paris,île-De-France 75008,france
Industry
Staffing And Recruiting
NAICS
Employment Services
Employment Placement Agencies and Executive Search Services
Professional Employer Organizations
Employment Placement Agencies
Keywords
suivants :.
HQ
Paris, Île-de-France
Looking for a particular Keros Group employee's phone or email?

Keros Group Questions

News

Keros Therapeutics (NASDAQ:KROS) Major Shareholder Adar1 Capital Management, Llc Sells 5,389,264 Shares - MarketBeat

Keros Therapeutics (NASDAQ:KROS) Major Shareholder Adar1 Capital Management, Llc Sells 5,389,264 Shares MarketBeat

Keros Therapeutics: A Potential Dart Throw (NASDAQ:KROS) - Seeking Alpha

Keros Therapeutics: A Potential Dart Throw (NASDAQ:KROS) Seeking Alpha

Keros Therapeutics Announces Review of Strategic Alternatives - GlobeNewswire

Keros Therapeutics Announces Review of Strategic Alternatives GlobeNewswire

Activist investor demands Keros 'aggressively' cut costs just weeks after layoffs - Fierce Biotech

Activist investor demands Keros 'aggressively' cut costs just weeks after layoffs Fierce Biotech

Keros Therapeutics adopts poison pill as it explores options, including sale - Reuters

Keros Therapeutics adopts poison pill as it explores options, including sale Reuters

Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial - Yahoo Finance

Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial Yahoo Finance

New Safety Signals Force Keros to Fully Terminate Mid-Stage PAH Study - BioSpace

New Safety Signals Force Keros to Fully Terminate Mid-Stage PAH Study BioSpace

Keros shares collapse on ‘unanticipated’ setback for lung disease drug - BioPharma Dive

Keros shares collapse on ‘unanticipated’ setback for lung disease drug BioPharma Dive

Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path (KROS) - Seeking Alpha

Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path (KROS) Seeking Alpha

Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value - GlobeNewswire

Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value GlobeNewswire

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth - simplywall.st

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth simplywall.st

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics - Business Wire

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics Business Wire

Dykema Obtains $9+ Million Award in Arbitration for Client Against Billionaire Partner - Dykema

Dykema Obtains $9+ Million Award in Arbitration for Client Against Billionaire Partner Dykema

eToro adds 700 US stocks to offering - FX News Group

eToro adds 700 US stocks to offering FX News Group

Keros Therapeutics Announces Licensing Agreement and - GlobeNewswire

Keros Therapeutics Announces Licensing Agreement and GlobeNewswire

Keros Therapeutics (NASDAQ:KROS) Now Covered by Analysts at Wells Fargo & Company - Defense World

Keros Therapeutics (NASDAQ:KROS) Now Covered by Analysts at Wells Fargo & Company Defense World

Top Keros Group Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant